Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global
medical technology company focused on surgical solutions for the
treatment of spinal disorders, today reported financial and
operating results for the third quarter ended September 30, 2021.
Third Quarter 2021 Financial Highlights:
- Revenue for the third quarter of 2021 totaled $13.8 million,
compared to $14.0 million for the prior-year period
- Loss from operations totaled $1.4 million compared to operating
income of $0.8 million for the prior-year period
- Net loss incurred in the third quarter of 2021 totaled $1.8
million compared to a net loss of $1.4 million for the prior-year
period
- Non-GAAP Adjusted EBITDA for the third quarter of 2021 totaled
a loss of $0.5 million, compared to Non-GAAP Adjusted EBITDA of
$1.5 million for the prior-year period
“While we have made significant investments that
have Xtant well-positioned for long-term growth, the impact from
the delta variant of COVID-19 created near-term pressures on
elective spinal procedures across our key markets,” said Sean
Browne, President and CEO of Xtant Medical. “In spite of these
challenges, we continued to grow our distribution network, expand
into adjacent markets and introduce exciting, new products to
market, all of which are important pillars of our growth strategy.
Our unyielding focus on bringing innovative biologics products to
patients in need allows us to fulfill our mission of honoring the
gift of donation.”
Third Quarter 2021 Financial
Results
Third quarter 2021 revenue was $13.8 million,
compared to $14.0 million for the same quarter in 2020. The
decrease in revenue was largely attributable to reductions in
elective procedures in key markets due to the impact of
COVID-19.
Gross margin for the third quarter of 2021 was
52.2%, compared to 66.0% for the same period in 2020. The decrease
was primarily attributable to a shift in product sales mix with an
increase in original equipment manufacturer (OEM) channel sales and
a reduction in independent agent channel sales, a temporary
reduction in manufacturing overhead absorption, and an increase in
the write-down of excess and obsolete inventory.
Operating expenses for the third quarter of 2021
totaled $8.6 million, compared to $8.5 million for the third
quarter of 2020. The increase was primarily due to greater salaries
and wage expenses and marketing and travel expenses, partially
offset by reduced employee compensation expense and lower
commissions resulting from a greater a mix of commission-free
private label and OEM sales.
Third quarter 2021 net loss totaled $1.8
million, or $0.02 per share, compared to the third quarter 2020 net
loss of $1.4 million, or $0.10 per share.
Non-GAAP Adjusted EBITDA for the third quarter
of 2021 totaled a loss of $0.5 million, compared to Non-GAAP
Adjusted EBITDA of $1.5 million for the prior-year period. The
Company defines Adjusted EBITDA as net income/loss from operations
before depreciation, amortization and interest expense and
provision for income taxes, and as further adjusted to add back in
or exclude, as applicable, non-cash compensation, separation
related expenses, and litigation settlement reserves. A calculation
and reconciliation of Adjusted EBITDA to net loss can be found in
the attached financial tables.
Conference Call
Xtant Medical will host a webcast and conference
call to discuss the third quarter 2021 financial results on Friday,
November 12, 2021 at 9:00 AM ET. To access the webcast, Click Here.
To access the conference call, dial 866-682-6100 within the U.S. or
862-298-0702 outside the U.S. A replay of the call will be
available at www.xtantmedical.com, under “Investor Info.”
About Xtant Medical Holdings,
Inc.
Xtant Medical Holdings, Inc.
(www.xtantmedical.com) is a global medical technology company
focused on the design, development, and commercialization of a
comprehensive portfolio of orthobiologics and spinal implant
systems to facilitate spinal fusion in complex spine, deformity and
degenerative procedures. Xtant people are dedicated and talented,
operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and
registered trademarks of Xtant Medical Holdings, Inc. or its
affiliates, registered as indicated in the United States, and in
other countries. All other trademarks and trade names referred to
in this release are the property of their respective owners.
Non-GAAP Financial Measures
To supplement the Company’s consolidated
financial statements prepared in accordance with U.S. generally
accepted accounting principles (GAAP), the Company uses certain
non-GAAP financial measures in this release, including Adjusted
EBITDA. Reconciliations of the non-GAAP financial measures used in
this release to the most comparable GAAP measures for the
respective periods can be found in tables later in this release.
The Company’s management believes that the presentation of these
measures provides useful information to investors. These measures
may assist investors in evaluating the Company’s operations, period
over period. Management uses the non-GAAP measures in this release
internally for evaluation of the performance of the business,
including the allocation of resources. Investors should consider
non-GAAP financial measures only as a supplement to, not as a
substitute for or as superior to, measures of financial performance
prepared in accordance with GAAP.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
that are predictive in nature, that depend upon or refer to future
events or conditions, or that include words such as “intends,”
‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’
‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going
forward,” similar expressions or the negative thereof, and the use
of future dates. Forward-looking statements in this release include
the Company’s continued investment in its growth initiatives and
their impact on the Company’s future growth strategy, operating
results and financial performance. The Company cautions that its
forward-looking statements by their nature involve risks and
uncertainties, and actual results may differ materially depending
on a variety of important factors, including, among others: the
Company’s future operating results and financial performance; the
ability to increase or maintain revenue; possible future impairment
charges to long-lived assets and goodwill and write-downs of excess
inventory if revenues continue to decrease; the ability to remain
competitive; the ability to innovate, develop and introduce new
products; the ability to engage and retain new and existing
independent distributors and agents and qualified personnel and the
Company’s dependence on key independent agents for a significant
portion of its revenue; the effect of the COVID-19 pandemic and
hospital staffing shortages on the Company’s business, operating
results and financial condition, especially when they affect key
markets; the Company’s ability to implement successfully its future
growth initiatives and risks associated therewith; the effect of
product sales mix changes on the Company’s financial results;
government and third-party coverage and reimbursement for Company
products; the ability to obtain and maintain regulatory approvals
and comply with government regulations; the effect of product
liability claims and other litigation to which the Company may be
subject; the effect of product recalls and defects; the ability to
obtain and protect Company intellectual property and proprietary
rights and operate without infringing the rights of others; the
ability to service Company debt, comply with its debt covenants and
access additional indebtedness; the ability to obtain additional
financing on favorable terms or at all; and other factors.
Additional risk factors are contained in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2020 filed with
the Securities and Exchange Commission (SEC) on February 24, 2021
and subsequent SEC filings by the Company, including without
limitation its most recent Quarterly Report on Form 10-Q for the
quarter ended September 30, 2021 anticipated to be filed with the
SEC. Investors are encouraged to read the Company’s filings with
the SEC, available at www.sec.gov, for a discussion of these and
other risks and uncertainties. The Company undertakes no obligation
to release publicly any revisions to any forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events, except as required
by law. All forward-looking statements attributable to the Company
or persons acting on its behalf are expressly qualified in their
entirety by this cautionary statement.
Investor Relations Contact
David CareyLazar FINNPh: 212-867-1762Email:
david.carey@finnpartners.com
|
XTANT MEDICAL HOLDINGS, INC. |
CONDENSED CONSOLIDATED BALANCE SHEETS |
(In thousands, except number of shares and par value) |
|
|
As ofSeptember 30,2021 |
|
As ofDecember 31,2020 |
|
|
(Unaudited) |
|
|
ASSETS |
|
|
|
|
Current Assets: |
|
|
|
|
Cash and cash equivalents |
|
$ |
18,175 |
|
|
$ |
2,341 |
|
Restricted Cash |
|
|
439 |
|
|
|
- |
|
Trade accounts receivable, net of allowance for credit losses and
doubtful accounts of $576 and $653, respectively |
|
|
6,321 |
|
|
|
6,880 |
|
Inventories |
|
|
19,708 |
|
|
|
21,408 |
|
Prepaid and other current assets |
|
|
945 |
|
|
|
736 |
|
Total current assets |
|
|
45,588 |
|
|
|
31,365 |
|
|
|
|
|
|
Property and equipment, net |
|
|
4,971 |
|
|
|
4,347 |
|
Right-of -use asset, net |
|
|
1,369 |
|
|
|
1,690 |
|
Goodwill |
|
|
3,205 |
|
|
|
3,205 |
|
Intangible assets, net |
|
|
414 |
|
|
|
457 |
|
Other assets |
|
|
244 |
|
|
|
402 |
|
Total Assets |
|
$ |
55,791 |
|
|
$ |
41,466 |
|
|
|
|
|
|
LIABILITIES & STOCKHOLDERS' EQUITY |
|
|
|
|
Current Liabilities: |
|
|
|
|
Accounts payable |
|
$ |
2,355 |
|
|
$ |
2,947 |
|
Accrued liabilities |
|
|
4,079 |
|
|
|
5,462 |
|
Current portion of lease liability |
|
|
451 |
|
|
|
423 |
|
Finance lease obligations |
|
|
31 |
|
|
|
20 |
|
Line of credit |
|
|
3,488 |
|
|
|
- |
|
Current portion of long-term debt |
|
|
- |
|
|
|
16,797 |
|
Total current liabilities |
|
|
10,404 |
|
|
|
25,649 |
|
Long-term Liabilities: |
|
|
|
|
Lease liability, less current portion |
|
|
961 |
|
|
|
1,303 |
|
Finance lease obligations, less current portion |
|
|
111 |
|
|
|
- |
|
Long-term debt, plus premium and less issuance costs |
|
|
11,678 |
|
|
|
- |
|
Total Liabilities |
|
|
23,154 |
|
|
|
26,952 |
|
|
|
|
|
|
Stockholders' Equity (Deficit) |
|
|
|
|
Preferred stock, $0.000001 par value; 10,000,000 shares authorized;
no shares issued and outstanding |
|
|
- |
|
|
|
- |
|
Common stock, $0.000001 par value; 300,000,000 shares authorized;
86,796,175 shares issued and outstanding as of September 30, 2021
and 77,573,680 shares issued and outstanding as of December 31,
2020 |
|
|
- |
|
|
|
- |
|
Additional paid-in capital |
|
|
265,539 |
|
|
|
244,850 |
|
Accumulated deficit |
|
|
(232,902 |
) |
|
|
(230,336 |
) |
Total Stockholders’ Equity |
|
|
32,637 |
|
|
|
14,514 |
|
|
|
|
|
|
Total Liabilities & Stockholders’ Equity |
|
$ |
55,791 |
|
|
$ |
41,466 |
|
|
|
|
|
|
XTANT MEDICAL HOLDINGS, INC. |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(Unaudited, in thousands, except number of shares and per share
amounts) |
|
|
|
Three Months EndedSeptember 30, |
|
Nine Months EndedSeptember 30, |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Revenue |
|
|
|
|
|
|
|
|
Orthopedic product sales |
|
$ |
13,743 |
|
|
$ |
13,980 |
|
|
$ |
41,193 |
|
|
$ |
39,207 |
|
Other revenue |
|
|
34 |
|
|
|
36 |
|
|
|
100 |
|
|
|
115 |
|
Total revenue |
|
|
13,777 |
|
|
|
14,016 |
|
|
|
41,293 |
|
|
|
39,322 |
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
6,586 |
|
|
|
4,768 |
|
|
|
16,498 |
|
|
|
13,913 |
|
Gross profit |
|
|
7,191 |
|
|
|
9,248 |
|
|
|
24,795 |
|
|
|
25,409 |
|
|
|
|
|
|
|
|
|
|
Gross profit % |
|
|
52.2 |
% |
|
|
66.0 |
% |
|
|
60.0 |
% |
|
|
64.6 |
% |
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
General and administrative |
|
|
3,107 |
|
|
|
3,042 |
|
|
|
10,307 |
|
|
|
10,293 |
|
Sales and marketing |
|
|
5,267 |
|
|
|
5,270 |
|
|
|
15,712 |
|
|
|
15,578 |
|
Research and development |
|
|
262 |
|
|
|
176 |
|
|
|
719 |
|
|
|
529 |
|
Total operating expenses |
|
|
8,636 |
|
|
|
8,488 |
|
|
|
26,738 |
|
|
|
26,400 |
|
|
|
|
|
|
|
|
|
|
(Loss) Income from operations |
|
|
(1,445 |
) |
|
|
760 |
|
|
|
(1,943 |
) |
|
|
(991 |
) |
|
|
|
|
|
|
|
|
|
Other income |
|
|
|
|
|
|
|
|
Interest expense |
|
|
(329 |
) |
|
|
(2,097 |
) |
|
|
(529 |
) |
|
|
(5,258 |
) |
Total Other Expense |
|
|
(329 |
) |
|
|
(2,097 |
) |
|
|
(529 |
) |
|
|
(5,258 |
) |
Net Loss Before Provision for Income Taxes |
|
|
(1,774 |
) |
|
|
(1,337 |
) |
|
|
(2,472 |
) |
|
|
(6,249 |
) |
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
(30 |
) |
|
|
(23 |
) |
|
|
(94 |
) |
|
|
(68 |
) |
Net Loss |
|
$ |
(1,804 |
) |
|
$ |
(1,360 |
) |
|
$ |
(2,566 |
) |
|
$ |
(6,317 |
) |
|
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.02 |
) |
|
$ |
(0.10 |
) |
|
$ |
(0.03 |
) |
|
$ |
(0.48 |
) |
Dilutive |
|
$ |
(0.02 |
) |
|
$ |
(0.10 |
) |
|
$ |
(0.03 |
) |
|
$ |
(0.48 |
) |
|
|
|
|
|
|
|
|
|
Shares used in the computation: |
|
|
|
|
|
|
|
|
Basic |
|
|
86,763,210 |
|
|
|
13,231,823 |
|
|
|
84,926,656 |
|
|
|
13,210,386 |
|
Dilutive |
|
|
86,763,210 |
|
|
|
13,231,823 |
|
|
|
84,926,656 |
|
|
|
13,210,386 |
|
|
|
|
|
|
|
|
|
|
XTANT MEDICAL HOLDINGS, INC. |
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS |
(Unaudited, in thousands) |
|
|
Nine Months EndedSeptember 30, |
|
|
|
2021 |
|
|
|
2020 |
|
Operating activities: |
|
|
|
|
Net loss |
|
$ |
(2,566 |
) |
|
$ |
(6,317 |
) |
Adjustments to reconcile net loss to net cash provided by operating
activities: |
|
|
|
|
Depreciation and amortization |
|
|
1,041 |
|
|
|
1,658 |
|
Gain on disposal of fixed assets |
|
|
(164 |
) |
|
|
(307 |
) |
Non-cash interest |
|
|
38 |
|
|
|
5,245 |
|
Non-cash rent expense |
|
|
8 |
|
|
|
12 |
|
Stock-based compensation |
|
|
1,501 |
|
|
|
726 |
|
Provision for reserve on accounts receivable |
|
|
(25 |
) |
|
|
296 |
|
Provision for excess and obsolete inventory |
|
|
572 |
|
|
|
429 |
|
|
|
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable |
|
|
584 |
|
|
|
2,463 |
|
Inventories |
|
|
1,128 |
|
|
|
(4,999 |
) |
Prepaid and other assets |
|
|
(126 |
) |
|
|
(890 |
) |
Accounts payable |
|
|
(592 |
) |
|
|
626 |
|
Accrued liabilities |
|
|
(1,383 |
) |
|
|
(589 |
) |
Net cash provide by (used in) operating activities |
|
|
16 |
|
|
|
(1,647 |
) |
Investing activities: |
|
|
|
|
Purchases of property and equipment |
|
|
(1,489 |
) |
|
|
(907 |
) |
Proceeds from sale of fixed assets |
|
|
194 |
|
|
|
173 |
|
Net cash used in investing activities |
|
|
(1,295 |
) |
|
|
(734 |
) |
Financing activities: |
|
|
|
|
Payment of taxes from withholding of common stock on vesting of
restricted stock units |
|
|
(23 |
) |
|
|
- |
|
Payments on financing leases |
|
|
(42 |
) |
|
|
(115 |
) |
Costs associated with refinancing |
|
|
(136 |
) |
|
|
- |
|
Payments on long-term debt |
|
|
(411 |
) |
|
|
- |
|
Borrowings on line of credit |
|
|
22,767 |
|
|
|
Repayments of line of credit |
|
|
(23,029 |
) |
|
|
- |
|
Proceeds from private placement, net of cash issuance costs |
|
|
18,426 |
|
|
|
- |
|
Net cash used in financing activities |
|
|
17,552 |
|
|
|
(115 |
) |
|
|
|
|
|
Net change in cash and cash equivalents |
|
|
16,273 |
|
|
|
(2,496 |
) |
Cash and cash equivalents at beginning of period |
|
|
2,341 |
|
|
|
5,237 |
|
Cash and cash equivalents at end of period |
|
$ |
18,614 |
|
|
$ |
2,741 |
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of cash and restricted cash reported in the
condensed consolidated balance sheets |
|
|
|
|
Cash and cash equivalents |
|
$ |
18,175 |
|
|
$ |
2,741 |
|
Restricted cash |
|
|
439 |
|
|
|
- |
|
Total cash and restricted cash reported in the condensed
consolidated balance sheets |
|
$ |
18,614 |
|
|
$ |
2,741 |
|
|
|
|
|
|
XTANT MEDICAL HOLDINGS, INC. |
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED
EBITDA |
(Unaudited, in thousands) |
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedSeptember 30, |
|
Nine Months EndedSeptember 30, |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
Net Loss |
|
$ |
(1,804 |
) |
|
$ |
(1,360 |
) |
|
$ |
(2,566 |
) |
|
$ |
(6,317 |
) |
|
|
|
|
|
|
|
|
|
Other expense |
|
|
21 |
|
|
|
(1 |
) |
|
|
62 |
|
|
|
5 |
|
Depreciation and amortization |
|
|
310 |
|
|
|
504 |
|
|
|
1,041 |
|
|
|
1,658 |
|
Interest expense |
|
|
329 |
|
|
|
2,097 |
|
|
|
529 |
|
|
|
5,258 |
|
Tax expense |
|
|
30 |
|
|
|
23 |
|
|
|
94 |
|
|
|
68 |
|
Non-GAAP EBITDA |
|
|
(1,114 |
) |
|
|
1,263 |
|
|
|
(840 |
) |
|
|
672 |
|
|
|
|
|
|
|
|
|
|
Non-GAAP EBITDA/Total revenue |
|
|
-8.1 |
% |
|
|
9.0 |
% |
|
|
-2.0 |
% |
|
|
1.7 |
% |
|
|
|
|
|
|
|
|
|
NON-GAAP ADJUSTED EBITDA CALCULATION |
|
|
|
|
|
|
|
|
Non-cash compensation |
|
|
580 |
|
|
|
237 |
|
|
|
1,501 |
|
|
|
726 |
|
Separation-related expenses |
|
|
- |
|
|
|
(50 |
) |
|
|
- |
|
|
|
699 |
|
Change in warrant derivative liability |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(7 |
) |
Litigation reserve |
|
|
- |
|
|
|
5 |
|
|
|
550 |
|
|
|
5 |
|
Non-GAAP Adjusted EBITDA |
|
$ |
(534 |
) |
|
$ |
1,455 |
|
|
$ |
1,211 |
|
|
$ |
2,095 |
|
|
|
|
|
|
|
|
|
|
Non-GAAP Adjusted EBITDA/Total revenue |
|
|
-3.9 |
% |
|
|
10.4 |
% |
|
|
2.9 |
% |
|
|
5.3 |
% |
|
|
|
|
|
|
|
|
|
Xtant Medical (AMEX:XTNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xtant Medical (AMEX:XTNT)
Historical Stock Chart
From Apr 2023 to Apr 2024